Longer gap in Pfizer-BioNTech COVID vaccines boosts antibody levels: Study

A longer gap between first and second doses of the Pfizer-BioNTech COVID-19 vaccine generates strong antibody and T cell immune responses, UK researchers have found. The study, led by the University of Oxford, in collaboration with the Universities of Birmingham, Newcastle, Liverpool, Sheffield, and supported by the UK Coronavirus Immunology Consortium, is one of the most comprehensive studies into the immune response generated by the Pfizer COVID-19 vaccine to date.

A longer gap between first and second doses of the Pfizer-BioNTech COVID-19 vaccine generates strong antibody and T cell immune responses, UK researchers have found. The study, led by the University of Oxford, in collaboration with the Universities of Birmingham, Newcastle, Liverpool, Sheffield, and supported by the UK Coronavirus Immunology Consortium, is one of the most comprehensive studies into the immune response generated by the Pfizer COVID-19 vaccine to date. July 24, 2021 at 09:37PM https://ift.tt/3ryZYSb